Novartis and Takeda drugs gain rare blood cancer routine use on NHS
The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.
Therapy Area
Bayer’s heart failure drug bound for NHS on NICE recommendation
Women’s health attracted record equity in 2025 as companies share capital
EAN 2026: Bocunebart’s promise as migraine preventive in treatment-refractory patients
Sanofi aims for Nexviazyme approval in younger Pompe disease patients
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1
EHA26: Epcoritamab improves PFS but not OS in R/R LBCL
